Nothing Cleans Like Oral‑B iO: The Electric Toothbrush That Cleans Deeper, Smarter and Better
10.9.2026 10:00:00 EEST | Business Wire | Press release
Oral‑B, the #1 brand most used by dentists worldwide, today spotlights its most advanced brushing technology: the Oral‑B iO range. Powered by a unique 2-in-1 cleaning technology, iO is engineered to clean deeper into every gap, brush smarter with real-time pressure guidance, and deliver results that are clinically proven to be better. The proof is everything — and nothing cleans like Oral‑B iO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904320713/en/
Oral-B iO10
Most people know that an electric toothbrush outperforms a manual one — but not everyone knows why, or what makes one electric brush stand apart from another. Oral‑B iO makes the difference clear: deeper, smarter, better — everywhere.
Cleans Deeper: The Technology Behind the Clean
At the heart of iO is a unique 2-in-1 technology: ultra-precise round head rotations work together with bristle-generated micro vibrations to break down and remove plaque simultaneously. Power is delivered directly to each bristle tip via a Linear Magnetic Drive — meaning every bristle actively moves, reaching into the spaces that flat brushes skip over.
The round brush head is the key. Inspired by professional dental instruments, it wraps around each individual tooth rather than sweeping across multiple at once. This means iO cleans from in-between teeth to along the gumline, behind teeth and deep in back molars — delivering a consistently deeper clean across the full mouth, every brush, every time, everywhere.
Cleans Smarter: Guided Brushing, Perfect Pressure
Oral‑B iO doesn’t just clean powerfully — it ensures you clean correctly. Most people don’t realise they’re applying too much or too little pressure when they brush, which can lead to gum damage or an incomplete clean. Oral‑B iO is the only brush that tells you all three: when you’re pressing too hard, when your pressure is just right, and when you’re being too gentle to clean effectively.
A 360° visible smart pressure sensor uses colour-coded light feedback to guide brushing technique in real time:
- Green light: optimal pressure — brushing is correctly calibrated for effective plaque removal.
- Red light: too much force — reduces risk of gum damage.
- White light: more pressure needed — prompts more thorough coverage.
So you always know you’re brushing just right — a powerful enough clean to effectively remove plaque, yet gentle enough to protect your gums.
- For iO9 and iO10 users: Smart Adapt Mode goes even further automatically adapting to the way you brush in real time to optimise rotation and pressure every millisecond.
- For iO6 to iO10 users: they can also connect to the Oral‑B App, which uses position detection to track how and where you’re brushing in real time — so you never miss a spot.
- And across the full iO range from iO2 to iO10, a built-in 30-second reminder vibrates to prompt you to move to the next area of your mouth, helping you achieve a complete, consistent clean every time.
Cleans Better: What the Evidence Shows
The Oral‑B iO advantage is not just felt — it is proven. Electric toothbrushes have long been shown to outperform manual brushing, with long-term research demonstrating that electric toothbrush users experience 20% less tooth loss compared to manual users*, thanks to more effective plaque removal and a reduced rate of gum disease development. Oral‑B iO takes that further still.
Across multiple independent clinical studies, Oral‑B iO delivers measurably superior outcomes:
- 100% more plaque removal than a manual toothbrush.
- 6x more plaque removal along the gumline than a manual toothbrush
- 14.5x higher odds of moving from non-healthy to healthy gums compared to regular manual toothbrush users.
- Up to 2x quieter than old generation Oral‑B brushes.
This isn’t a marginal improvement — it’s a categorically superior clean, delivering real oral health outcomes that make a difference patients and dentists can both see.
“Oral-B iO electric toothbrushes are clinically proven to remove twice as much plaque versus a manual toothbrush (with twice daily brushing) thanks to the gentle bristles that rotate and vibrate for a deeper clean, even in hard-to-reach-areas of the mouth. All iO models also feature a built-in 2-minute timer, helping you brush for the dentist-recommended length of time. By improving your daily brushing habits and taking better care of your teeth and gums, an electric toothbrush can help reduce your risk of cavities, gingivitis, and other oral health issues.” - Eva Castro Perea, Dentist and Senior Scientific Relations at Oral-B
For anyone looking to get more from their daily routine, Oral‑B iO offers something remarkable: a clean that is deeper, smarter and clinically proven to be better. Oral‑B iO doesn’t just promise a superior clean — it delivers one everywhere.
*20% less tooth loss in electric toothbrush users: Pitchika V, Pink C, Völzke H, Welk A, Kocher T, Holtfreter B. Long-term impact of powered toothbrush on oral health: 11-year cohort study. J Clin Periodontol. 2019.
About Oral-B
Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260904320713/en/
Contacts
For more information please contact: ORALCARERBU_MSL_TEAM_GBR@pgone.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom